720 related articles for article (PubMed ID: 35431535)
1. COVID-19 vaccines: their effectiveness against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its emerging variants.
Noor R; Shareen S; Billah M
Bull Natl Res Cent; 2022; 46(1):96. PubMed ID: 35431535
[TBL] [Abstract][Full Text] [Related]
2. The Biological Functions and Clinical Significance of SARS-CoV-2 Variants of Corcern.
Akkız H
Front Med (Lausanne); 2022; 9():849217. PubMed ID: 35669924
[TBL] [Abstract][Full Text] [Related]
3. Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine.
Melo-González F; Soto JA; González LA; Fernández J; Duarte LF; Schultz BM; Gálvez NMS; Pacheco GA; Ríos M; Vázquez Y; Rivera-Pérez D; Moreno-Tapia D; Iturriaga C; Vallejos OP; Berríos-Rojas RV; Hoppe-Elsholz G; Urzúa M; Bruneau N; Fasce RA; Mora J; Grifoni A; Sette A; Weiskopf D; Zeng G; Meng W; González-Aramundiz JV; González PA; Abarca K; Ramírez E; Kalergis AM; Bueno SM
Front Immunol; 2021; 12():747830. PubMed ID: 34858404
[TBL] [Abstract][Full Text] [Related]
4. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G
J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359
[TBL] [Abstract][Full Text] [Related]
5. COVID-19 Pandemic and Vaccines Update on Challenges and Resolutions.
Khan WH; Hashmi Z; Goel A; Ahmad R; Gupta K; Khan N; Alam I; Ahmed F; Ansari MA
Front Cell Infect Microbiol; 2021; 11():690621. PubMed ID: 34568087
[TBL] [Abstract][Full Text] [Related]
6. Serosurvey in SARS-CoV-2 inactivated vaccine-elicited neutralizing antibodies against authentic SARS-CoV-2 and its viral variants.
Zou L; Zhang H; Zheng Z; Jiang Y; Huang Y; Lin S; Yu J; Deng X; He J; Shen C; Li B
J Med Virol; 2022 Dec; 94(12):6065-6072. PubMed ID: 35931461
[TBL] [Abstract][Full Text] [Related]
7. Immune response of booster doses of BBIBP-CORV vaccines against the variants of concern of SARS-CoV-2.
Mahmoud S; Ganesan S; Al Kaabi N; Naik S; Elavalli S; Gopinath P; Ali AM; Bazzi L; Warren K; Zaher WA; Hosani FA
J Clin Virol; 2022 Jun; 150-151():105161. PubMed ID: 35439702
[TBL] [Abstract][Full Text] [Related]
8. Variants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Vaccine Effectiveness.
Tulimilli SV; Dallavalasa S; Basavaraju CG; Kumar Rao V; Chikkahonnaiah P; Madhunapantula SV; Veeranna RP
Vaccines (Basel); 2022 Oct; 10(10):. PubMed ID: 36298616
[TBL] [Abstract][Full Text] [Related]
9. Covid-19 vaccines and variants of concern: A review.
Hadj Hassine I
Rev Med Virol; 2022 Jul; 32(4):e2313. PubMed ID: 34755408
[TBL] [Abstract][Full Text] [Related]
10. Classical and Next-Generation Vaccine Platforms to SARS-CoV-2: Biotechnological Strategies and Genomic Variants.
Simões RSQ; Rodríguez-Lázaro D
Int J Environ Res Public Health; 2022 Feb; 19(4):. PubMed ID: 35206580
[TBL] [Abstract][Full Text] [Related]
11. Generation of neutralizing antibodies against Omicron, Gamma and Delta SARS-CoV-2 variants following CoronaVac vaccination.
Silva ARD; Villas-Boas LS; Tozetto-Mendoza TR; Honorato L; Paula A; Witkin SS; Mendes-Correa MC
Rev Inst Med Trop Sao Paulo; 2022; 64():e19. PubMed ID: 35239863
[TBL] [Abstract][Full Text] [Related]
12. The Impact of Evolving SARS-CoV-2 Mutations and Variants on COVID-19 Vaccines.
McLean G; Kamil J; Lee B; Moore P; Schulz TF; Muik A; Sahin U; Türeci Ö; Pather S
mBio; 2022 Apr; 13(2):e0297921. PubMed ID: 35352979
[TBL] [Abstract][Full Text] [Related]
13. Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines.
Yang Y; Zang J; Xu S; Zhang X; Yuan S; Wang H; Lavillette D; Zhang C; Huang Z
Viruses; 2021 Jul; 13(8):. PubMed ID: 34452287
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity Following Two Doses of the BBIBP-CorV Vaccine and a Third Booster Dose with a Viral Vector and mRNA COVID-19 Vaccines against Delta and Omicron Variants in Prime Immunized Adults with Two Doses of the BBIBP-CorV Vaccine.
Chansaenroj J; Suntronwong N; Kanokudom S; Assawakosri S; Yorsaeng R; Vichaiwattana P; Klinfueng S; Wongsrisang L; Srimuan D; Thatsanatorn T; Thongmee T; Auphimai C; Nilyanimit P; Wanlapakorn N; Sudhinaraset N; Poovorawan Y
Vaccines (Basel); 2022 Jul; 10(7):. PubMed ID: 35891235
[TBL] [Abstract][Full Text] [Related]
15. Neutralizing activity of BBIBP-CorV vaccine-elicited sera against Beta, Delta and other SARS-CoV-2 variants of concern.
Yu X; Wei D; Xu W; Liu C; Guo W; Li X; Tan W; Liu L; Zhang X; Qu J; Yang Z; Chen E
Nat Commun; 2022 Apr; 13(1):1788. PubMed ID: 35379815
[TBL] [Abstract][Full Text] [Related]
16. Emergency SARS-CoV-2 Variants of Concern: Novel Multiplex Real-Time RT-PCR Assay for Rapid Detection and Surveillance.
Chung HY; Jian MJ; Chang CK; Lin JC; Yeh KM; Chen CW; Hsieh SS; Hung KS; Tang SH; Perng CL; Chang FY; Wang CH; Shang HS
Microbiol Spectr; 2022 Feb; 10(1):e0251321. PubMed ID: 35196812
[TBL] [Abstract][Full Text] [Related]
17. Host Protective Immunity against Severe Acute Respiratory Coronavirus 2 (SARS-CoV-2) and the COVID-19 Vaccine-Induced Immunity against SARS-CoV-2 and Its Variants.
Noor R
Viruses; 2022 Nov; 14(11):. PubMed ID: 36423150
[TBL] [Abstract][Full Text] [Related]
18. A nasal omicron vaccine booster elicits potent neutralizing antibody response against emerging SARS-CoV-2 variants.
Lam JY; Ng YY; Yuen CK; Wong WM; Yuen KY; Kok KH
Emerg Microbes Infect; 2022 Dec; 11(1):964-967. PubMed ID: 35275039
[TBL] [Abstract][Full Text] [Related]
19. SARS-CoV-2 Neutralizing Antibodies: A Network Meta-Analysis across Vaccines.
Rogliani P; Chetta A; Cazzola M; Calzetta L
Vaccines (Basel); 2021 Mar; 9(3):. PubMed ID: 33807818
[No Abstract] [Full Text] [Related]
20. Serum Neutralizing Activity of mRNA-1273 against SARS-CoV-2 Variants.
Choi A; Koch M; Wu K; Dixon G; Oestreicher J; Legault H; Stewart-Jones GBE; Colpitts T; Pajon R; Bennett H; Carfi A; Edwards DK
J Virol; 2021 Nov; 95(23):e0131321. PubMed ID: 34549975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]